Patent: 8,906,847

Summary for Patent: 8,906,847

Title:	Prodrug comprising a drug linker conjugate
Abstract:	The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising a drug linker conjugate D-L, wherein -D is an amine containing biologically active moiety; and -L is a non-biologically active linker moiety -L.sup.1 represented by formula (I), wherein the dashed line indicates the attachment to the amine of the biologically active moiety and wherein R.sup.1, R.sup.1a, R.sup.2, R.sup.2a, R.sup.3, R.sup.3a, X, X.sup.1, X.sup.2, X.sup.3 have the meaning as indicated in the description and the claims and wherein L.sup.1 is substituted with one to four groups L.sup.2-Z and optionally further substituted, provided that the hydrogen marked with the asterisk in formula (I) is not replaced by a substituent; wherein L.sup.2 is a single chemical bond or a spacer; and Z is a carrier group. The invention also relates to A-L, wherein A is a leaving group, pharmaceutical composition comprising said prodrugs and their use as medicaments. ##STR00001##
Inventor(s):	Cleemann; Felix (Heidelberg, DE), Hersel; Ulrich (Heidelberg, DE), Kaden; Silvia (Heidelberg, DE), Rau; Harald (Heidelberg, DE), Wegge; Thomas (Heidelberg, DE)
Assignee:	Ascendis Pharma A/S (Hellerup, DK)
Application Number:	12/865,693
Patent Claims:	see list of patent claims

Details for Patent 8,906,847

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	01/15/1974		2028-02-01
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	12/27/1984		2028-02-01
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/15/1985		2028-02-01
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/16/1990		2028-02-01